Sarepta’s bad week raised questions about its gene therapy program. Here are some answers

Sarepta Therapeutics (SRPT) wasn’t directly implicated in the biotech sector’s credibility crisis last week, but that didn’t stop the company from running into trouble.

The “erroneous” disclosure last Thursday of a serious side effect affecting a single patient with Duchenne muscular dystrophy enrolled in Sarepta’s gene therapy clinical trial sowed

confusion, concern, and anger. The stock price took a hit, recovered, then fell some more. All in, Sarepta shares lost 14%.

Monday and a new trading week give Sarepta an opportunity to reset, unless lingering concerns remain about what exactly happened to its Duchenne gene therapy program and why. Here are eight

burning questions and a stab at answers.